Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiovascular Diseases AND Coronary Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    470 result(s) found for: Cardiovascular Diseases AND Coronary Disease. Displaying page 22 of 24.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next»
    EudraCT Number: 2016-002299-28 Sponsor Protocol Number: 20110203 Start Date*: 2017-01-17
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Redu...
    Medical condition: Chronic Heart Failure With Reduced Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed) ES (Completed) HU (Completed) NL (Completed) GB (Completed) PT (Completed) PL (Completed) AT (Completed) SK (Completed) BG (Completed) LT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003859-12 Sponsor Protocol Number: 12-027 Start Date*: 2013-07-19
    Sponsor Name:RWTH Aachen University for the Medical Faculty, represented by Clinical Trial Center Aachen (CTC-A)
    Full Title: Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus
    Medical condition: patients with type 2 diabetes mellitus and vascular inflammation
    Disease: Version SOC Term Classification Code Term Level
    17.0 10018065 - General disorders and administration site conditions 10061218 Inflammation PT
    17.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005227-37 Sponsor Protocol Number: OLT1177-10 Start Date*: 2021-03-03
    Sponsor Name:Olatec Therapeutics LLC
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of ...
    Medical condition: COVID-19, cytokine release syndrome
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000885-40 Sponsor Protocol Number: 04-CL-1904 Start Date*: 2020-08-27
    Sponsor Name:Windtree Therapeutics, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC)
    Medical condition: Pre-Cardiogenic Shock
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003123-35 Sponsor Protocol Number: TRG 10-01 Start Date*: 2011-09-22
    Sponsor Name:University of Oxford
    Full Title: The impact of single versus double dose acetylsalicylic acid on platelet function in patients with type 2 diabetes (the "ASP Study").
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003776-40 Sponsor Protocol Number: CL-N-CSM-AV-III/05/12 Start Date*: 2013-11-08
    Sponsor Name:Dr. Franz Köhler Chemie GmbH
    Full Title: A Prospective Randomized Double Blind Multicenter Phase III Study Comparing two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N versus Custodiol
    Medical condition: Patients with aortic valve disease and has to undergo aortic valve surgery +/- bypass surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022630-92 Sponsor Protocol Number: AP214-CS007 Start Date*: 2010-11-05
    Sponsor Name:Action Pharma A/S
    Full Title: An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Su...
    Medical condition: Action Pharma is developing AP214 Acetate for the prevention of postsurgical kidney injury after cardiac surgery. Trial population is patients with increased risk for development of Kidney Inju...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10022117 - Injury, poisoning and procedural complications 10056675 Postoperative renal failure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022293-14 Sponsor Protocol Number: ANRS146OPTIMAL Start Date*: 2012-08-22
    Sponsor Name:Inserm-ANRS
    Full Title: Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defi...
    Medical condition: HIV infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002715-41 Sponsor Protocol Number: P130934 Start Date*: 2015-08-11
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: KAWAKINRA study, "A phase IIa multicenter trial to assess the efficacy and safety of Anakinra in patients with intraveinous immunoglobulin-resistant Kawasaki disease"
    Medical condition: Anakinra treatment is expected to reduce the early and long term mortality of patients with Kawasaki Disease (KD), by a rapid and sustained effect on vascular inflammation
    Disease: Version SOC Term Classification Code Term Level
    17.1 10047065 - Vascular disorders 10023320 Kawasaki's disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019461-29 Sponsor Protocol Number: ETAMI Start Date*: 2011-03-25
    Sponsor Name:Stiftung Institut für Herzinfarktforschung
    Full Title: ETAMI-Study: Early Thienopyridine treatment to improve primary PCI in Patients with Acute Myocardial Infarction
    Medical condition: Myocardial infarction <= 12 hours
    Disease: Version SOC Term Classification Code Term Level
    15.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005032-30 Sponsor Protocol Number: 2021-PDNO-003 Start Date*: 2022-05-16
    Sponsor Name:Attgeno AB
    Full Title: An open-label, multicenter study to evaluate the DOSE, efficacy, safety and tolerability of PDNO (Nitrosooxypropanol) infusion in patients with pulmonary hypertension after cardiopulmonary bypass (...
    Medical condition: Acute Pulmonary Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023394-19 Sponsor Protocol Number: 9129 Start Date*: 2012-11-13
    Sponsor Name:Maatschap Cardiologie Isala
    Full Title: Early Beta blocker Administration before reperfusion in patients with ST-Elevation Myocardial Infarction who are planned to undergo primary PCI
    Medical condition: Patients with acute ST elevation myocardial infarction, scheduled for emergency coronary angioplasty
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10066641 Acute myocardial infarction, of anterior wall LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003772-74 Sponsor Protocol Number: MDCO-PCS-15-01 Start Date*: 2015-12-16
    Sponsor Name:The Medicines Company
    Full Title: A placebo-controlled, double-blind, randomized trial to compare the effect of different doses of ALN-PCSSC given as single or multiple subcutaneous injections in subjects with high cardiovascular r...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001846-90 Sponsor Protocol Number: MDCO-PCS-17-08 Start Date*: 2017-12-12
    Sponsor Name:The Medicines Company
    Full Title: A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO EVALUATE THE EFFECT OF 300 MG OF INCLISIRAN SODIUM GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (Completed) CZ (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002618-11 Sponsor Protocol Number: I8F-MC-GPGM Start Date*: 2019-05-06
    Sponsor Name:Eli Lilly and Company
    Full Title: Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-003376-49 Sponsor Protocol Number: MDCO-PCS-16-02 Start Date*: 2017-06-20
    Sponsor Name:The Medicines Company
    Full Title: An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects with Homozygous Familial Hypercholesterolemia
    Medical condition: Homozygous Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000608-40 Sponsor Protocol Number: No-DAPT-TAVI Start Date*: 2018-07-06
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: Aspirin versus Aspirin plus Clopidogrel in Patients Undergoing Transcatheter Aortic Valve Replacement: a Randomized Multicenter Study
    Medical condition: valvular aortic stenosis submitted to TAVI
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10002918 Aortic valve stenosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002752-20 Sponsor Protocol Number: LAN_POAF_01 Start Date*: 2020-12-17
    Sponsor Name:Medical University of Vienna
    Full Title: A prospective, randomized, double- blind, placebo- controlled study to evaluate the efficacy of Landiolol hydrochloride for prevention of atrial fibrillation in patients undergoing cardiac surgery
    Medical condition: Perioperative atrial fibrillation (POAF) is the most common arryhthmia after cardiac surgery with incidences ranging from 20% to 40%, depending on various patient's risk factors and the type of sur...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-001709-21 Sponsor Protocol Number: 2020PI073 Start Date*: 2020-04-29
    Sponsor Name:CHRU de Nancy
    Full Title: Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolis...
    Medical condition: Prevention of thromboembolic events in hospitalised COVID-19 infected patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10014523 Embolism and thrombosis HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003014-28 Sponsor Protocol Number: FARM12JCXN Start Date*: 2017-10-30
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: MULTICENTER RANDOMIZED STUDY ON THE EFFICACY OF IMMUNOSUPPRESSION IN PATIENTS WITH VIRUS-NEGATIVE INFLAMMATORY CARDIOMYOPATHY
    Medical condition: virus negative inflammatory cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 10:22:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA